Terms: = Skin cancer AND FUS, P35637, 2521, ENSG00000089280, TLS/CHOP, FUS-CHOP, CHOP, FUS1, TLS
345 results:
1. Tertiary lymphoid structures in cancer: maturation and induction.
Chen Y; Wu Y; Yan G; Zhang G
Front Immunol; 2024; 15():1369626. PubMed ID: 38690273
[TBL] [Abstract] [Full Text] [Related]
2. Analyses of tertiary lymphoid structures observed in cases of Merkel cell carcinoma showing spontaneous regression.
Nakamura M; Yoshimitsu M; Magara T; Kano S; Kato H; Morita A
Exp Dermatol; 2024 Mar; 33(3):e15062. PubMed ID: 38532566
[TBL] [Abstract] [Full Text] [Related]
3. Can we yet use tertiary lymphoid structures as predictive biomarkers for immunotherapy response in melanoma?
Padonou F; Vanhulst T; Langouo-Fontsa MD
Curr Opin Oncol; 2024 Mar; 36(2):63-68. PubMed ID: 38441065
[TBL] [Abstract] [Full Text] [Related]
4. PIKFYVE inhibitors trigger interleukin-24-dependent cell death of autophagy-dependent melanoma.
Roy A; Chakraborty AR; DePamphilis ML
Mol Oncol; 2024 Apr; 18(4):988-1011. PubMed ID: 38414326
[TBL] [Abstract] [Full Text] [Related]
5. Effects of immunogenic cell death-inducing chemotherapeutics on the immune cell activation and tertiary lymphoid structure formation in melanoma.
Zhao H; Zhao Y; Zhang S; Wang Z; Yu W; Dong N; Yang X; Zhang X; Sun Q; Hao X; Ren X
Front Immunol; 2024; 15():1302751. PubMed ID: 38384466
[TBL] [Abstract] [Full Text] [Related]
6. Immunotherapy for non-small cell lung cancer.
Kagamu H
Respir Investig; 2024 Mar; 62(2):307-312. PubMed ID: 38310751
[TBL] [Abstract] [Full Text] [Related]
7. SOX10-Internal Tandem Duplications and PLAG1 or HMGA2 fusions Segregate Eccrine-Type and Apocrine-Type Cutaneous Mixed Tumors.
Macagno N; Kervarrec T; Thanguturi S; Sohier P; Pissaloux D; Mescam L; Jullie ML; Frouin E; Osio A; Faisant M; Le Loarer F; Cribier B; Calonje E; Luna EVE; Massi D; Goto K; Nishida H; Paindavoine S; Houlier A; Tantot J; Benzerdjeb N; Tirode F; De la Fouchardière A; Battistella M
Mod Pathol; 2024 Mar; 37(3):100430. PubMed ID: 38266920
[TBL] [Abstract] [Full Text] [Related]
8. The molecular subtypes and clinical prognosis characteristic of tertiary lymphoid structures-related gene of cutaneous melanoma.
Li J; Chen G; Luo Y; Xu J; He J
Sci Rep; 2023 Dec; 13(1):23097. PubMed ID: 38155221
[TBL] [Abstract] [Full Text] [Related]
9. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment
Xu W; Lu J; Liu WR; Anwaier A; Wu Y; Tian X; Su JQ; Qu YY; Yang J; Zhang H; Ye D
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040418
[TBL] [Abstract] [Full Text] [Related]
10. Secondary malignancies among mantle cell lymphoma patients.
Abalo KD; Smedby KE; Ekberg S; Eloranta S; Pahnke S; Albertsson-Lindblad A; Jerkeman M; Glimelius I
Eur J Cancer; 2023 Dec; 195():113403. PubMed ID: 37952281
[TBL] [Abstract] [Full Text] [Related]
11. Sono-activated materials for enhancing focused ultrasound ablation: Design and application in biomedicine.
Liao M; Du J; Chen L; Huang J; Yang R; Bao W; Zeng K; Wang W; Aphan BC; Wu Z; Ma L; Lu Q
Acta Biomater; 2024 Jan; 173():36-50. PubMed ID: 37939816
[TBL] [Abstract] [Full Text] [Related]
12. Case report: Successful treatment of Chidamide in a refractory/recurrent SPTCL with ARID1A mutation on the basis of chop plus auto-HSCT.
Zhang N; Zhang S; Ma L; Qiu L; Meng QL; Cai J; Xu Z; Yao H; Fan FY
Medicine (Baltimore); 2023 Oct; 102(40):e35413. PubMed ID: 37800816
[TBL] [Abstract] [Full Text] [Related]
13. Response and local control in patients treated with low-dose radiotherapy for tumoral mycosis fungoides.
Pena J; Cull D; Strowd LC; Vaidya R; Seegars MB; Ahn C; Winkfield KM; Hughes RT
Leuk Lymphoma; 2023 Dec; 64(13):2202-2207. PubMed ID: 37671707
[TBL] [Abstract] [Full Text] [Related]
14. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
Ding L; Sun L; Bu MT; Zhang Y; Scott LN; Prins RM; Su MA; Lechner MG; Hugo W
Front Immunol; 2023; 14():1176994. PubMed ID: 37435085
[TBL] [Abstract] [Full Text] [Related]
15. Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes.
Karapetyan L; AbuShukair HM; Li A; Knight A; Al Bzour AN; MacFawn IP; Thompson ZJ; Chen A; Yang X; Dadey R; Karunamurthy A; De Stefano DV; Sander C; Kunning SR; Najjar YG; Davar D; Luke JJ; Gooding W; Bruno TC; Kirkwood JM; Storkus WJ
Front Immunol; 2023; 14():1171978. PubMed ID: 37435077
[TBL] [Abstract] [Full Text] [Related]
16. Shikonin Causes Non-apoptotic Cell Death in B16F10 Melanoma.
Ahmad H; Crotts MS; Jacobs JC; Baer RW; Cox JL
Anticancer Agents Med Chem; 2023; 23(16):1880-1887. PubMed ID: 37393553
[TBL] [Abstract] [Full Text] [Related]
17. Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy.
Sah VR; Jespersen H; Karlsson J; Nilsson LM; Bergqvist M; Johansson I; Carneiro A; Helgadottir H; Levin M; Ullenhag G; Ståhlberg A; Olofsson Bagge R; Nilsson JA; Ny L
Cancer Res Commun; 2023 May; 3(5):884-895. PubMed ID: 37377898
[TBL] [Abstract] [Full Text] [Related]
18. BS148 Reduces the Aggressiveness of Metastatic Melanoma via Sigma-2 Receptor Targeting.
Sorbi C; Belluti S; Atene CG; Marocchi F; Linciano P; Roy N; Paradiso E; Casarini L; Ronsisvalle S; Zanocco-Marani T; Brasili L; Lanfrancone L; Imbriano C; Di Rocco G; Franchini S
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298633
[TBL] [Abstract] [Full Text] [Related]
19. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas.
Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S
Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021
[TBL] [Abstract] [Full Text] [Related]
20. Mutational signatures and increased retrotransposon insertions in xeroderma pigmentosum variant skin tumors.
Corradi C; Vilar JB; Buzatto VC; de Souza TA; Castro LP; Munford V; De Vecchi R; Galante PAF; Orpinelli F; Miller TLA; Buzzo JL; Sotto MN; Saldiva P; de Oliveira JW; Chaibub SCW; Sarasin A; Menck CFM
Carcinogenesis; 2023 Aug; 44(6):511-524. PubMed ID: 37195263
[TBL] [Abstract] [Full Text] [Related]
[Next]
